The Greater Pennsylvania chapter of the Alzheimer’s Association says it’s been a productive and exciting year when it comes ...

Microglia have been revealed to first help spread Alzheimer’s disease pathology across the brain and then activate to limit ...

According to Phipps, the drugs currently available to treat Alzheimer’s have only eased the symptoms rather than stop its ...

Anavex Life Sciences' ANAVEX 2-73 shows promise in treating Alzheimer's, with strong efficacy in slowing cognitive and ...

Plasma p-tau217 immunoassay offers accurate detection of Alzheimer’s disease pathology, supporting early diagnosis and ...

This review provides an overview of Alzheimer’s disease (AD), discussing its complex pathophysiology, risk factors, and ...

Early research links the human cytomegalovirus, a type of herpes virus found in the gut, to the development of Alzheimer’s ...

Study to assess ability of GAL-101 eye drops in slowing or stopping the growth of geographic atrophy, a severe form of ...

In a deal worth $100 million up front and up to $1.25 billion in milestone payments, Bioarctic AB licensed its pyroglutamate-amyloid-β (pyroglutamate-Aβ) antibody program to Bristol Myers Squibb Co.

Why is age the strongest risk factor for Alzheimer’s disease? In the December 10 Science Signaling ... As SIRT6 peters out, more APP remains to generate Aβ peptides. Indeed, co-first authors Bai and ...

BioArctic's PyroGlu-Aβ antibody program consists of novel antibodies targeting a specific truncated, pyroglutamate modified form of amyloid-beta. Monomers of PyroGlu-Aβ are highly prone to aggregate, ...

Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced topline results from the exploratory Phase 2 ‘SHIMMER’ study ...